Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XERS
stocks logo

XERS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
81.38M
+35.42%
0.003
-103.03%
83.23M
+38.45%
0.022
-172.23%
92.63M
+29.49%
0.003
-105.55%
Estimates Revision
The market is revising Upward the revenue expectations for Xeris Biopharma Holdings, Inc. (XERS) for FY2025, with the revenue forecasts being adjusted by 0.33% over the past three months. During the same period, the stock price has changed by -14.39%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.33%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+22.23%
In Past 3 Month
Stock Price
Go Down
down Image
-14.39%
In Past 3 Month
Wall Street analysts forecast XERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XERS is 12.33 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast XERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XERS is 12.33 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.720
sliders
Low
9.00
Averages
12.33
High
18.00
Current: 6.720
sliders
Low
9.00
Averages
12.33
High
18.00
Piper Sandler
David Amsellem
Neutral
maintain
$6 -> $8
2025-11-07
Reason
Piper Sandler
David Amsellem
Price Target
$6 -> $8
2025-11-07
maintain
Neutral
Reason
Piper Sandler analyst David Amsellem raised the firm's price target on Xeris Biopharma to $8 from $6 and keeps a Neutral rating on the shares. The firm notes Xeris reported a Q3 net earnings per share of 0c on total revenues of $74.4M, compared to Street estimates of 1c and $74.2M, respectively. Notably, Recorlev continues to benefit from an expanding hypercortisolism space, positioning the company for sustainable cash generation, Piper adds.
Oppenheimer
Leland Gershell
Outperform
maintain
$8 -> $18
2025-10-29
Reason
Oppenheimer
Leland Gershell
Price Target
$8 -> $18
2025-10-29
maintain
Outperform
Reason
Oppenheimer analyst Leland Gershell raised the firm's price target on Xeris Biopharma to $18 from $8 and keeps an Outperform rating on the shares. Motivated by bullish commentary from the firm's recent endocrinologist expert call, Oppenheimer has revised its Xeris model to include value contribution from the company's subcutaneous levothyroxine candidate. XP-8121 is slated to enter a Phase 3 hypothyroidism trial in the first half of 2026, and the firm believes this once-weekly injectable's favorable Phase 2 performance derisks remaining development. Oppenheimer forecasts $1.3B peak sales, as may be generated from just 5% uptake into our estimated 2.6M U.S. adults with poorly controlled hypothyroidism following anticipated launch in the 2030 timeframe. It expects XP-8121's progress toward commercialization along with continued commercial execution to drive outperformance.
H.C. Wainwright
Buy
initiated
$10
2025-08-12
Reason
H.C. Wainwright
Price Target
$10
2025-08-12
initiated
Buy
Reason
H.C. Wainwright assumed coverage of Xeris Biopharma with a Buy rating and $10 price target. The firm believes the commercial potential of the company's commercial portfolio remains "meaningfully underappreciated." The portfolio has the potential to drive further Xeris stock appreciation, the analyst tells investors in a research note.
Oppenheimer
Oppenheimer
Outperform
maintain
$7 -> $8
2025-08-08
Reason
Oppenheimer
Oppenheimer
Price Target
$7 -> $8
2025-08-08
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Xeris Biopharma to $8 from $7 and keeps an Outperform rating on the shares following quarterly results. The firm cites outlook for continued commercial execution and sustainable growth.
Oppenheimer
Oppenheimer
Outperform
maintain
$6 -> $7
2025-05-09
Reason
Oppenheimer
Oppenheimer
Price Target
$6 -> $7
2025-05-09
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Xeris Biopharma to $7 from $6 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 total revenue of $60.1M, which topped OpCo/consensus estimates on solid Recorlev/Gvoke performance and Keveyis durability. Management tightened full-year guidance to $260M-$275M from $255M-$275M, and the firm expects adjusted EBITDA to be consistently positive going forward. No apparent tariff threat as manufacturing is wholly domestic. Oppenheimer looks forward to the June 3 analyst day at which a key focus will be the company's subcutaneous levothyroxine for hypothyroidism.
Craig-Hallum
Chase Knickerbocker
Strong Buy
Maintains
$5 → $6.5
2025-03-07
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$5 → $6.5
2025-03-07
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Xeris Biopharma Holdings Inc (XERS.O) is 55.22, compared to its 5-year average forward P/E of -8.11. For a more detailed relative valuation and DCF analysis to assess Xeris Biopharma Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.11
Current PE
55.22
Overvalued PE
31.57
Undervalued PE
-47.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-14.64
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
96.02
Undervalued EV/EBITDA
-125.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.14
Current PS
0.00
Overvalued PS
2.89
Undervalued PS
1.39
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

XERS News & Events

Events Timeline

(ET)
2025-12-01
07:18:00
Xeris Biopharma Secures Patent Allowance for XP-8121 Product Candidate
select
2025-11-06 (ET)
2025-11-06
07:39:59
Xeris Biopharma Announces Q3 Earnings Per Share of 0c, Matching Expectations
select
2025-08-27 (ET)
2025-08-27
08:37:30
American Regent Introduces Gvoke VialDx
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-02NASDAQ.COM
Xeris Biopharma Holdings (XERS) Experiences Oversold Conditions

  • Xeris Biopharma Holdings Inc Performance: Xeris Biopharma Holdings Inc (XERS) shares have entered oversold territory with an RSI of 29.4, trading as low as $6.65 per share, compared to the S&P 500 ETF's RSI of 59.8.

  • Potential Buying Opportunity: The low RSI reading may indicate that the recent heavy selling is nearing exhaustion, suggesting potential buying opportunities for bullish investors.

  • 52-Week Range: XERS's 52-week low is $3.14 and the high is $10.08, with the last trade recorded at $6.65.

  • Author's Views: The opinions expressed in the article are those of the author and do not necessarily reflect the views of Nasdaq, Inc.

[object Object]
Preview
6.5
11-07NASDAQ.COM
Experts Predict FHLC Will Hit $81

  • Fidelity MSCI Health Care Index ETF Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $81.28, indicating a potential upside of 15.88% from its current trading price of $70.14.

  • Notable Holdings with Upside Potential: Key underlying holdings of FHLC, such as Xeris Biopharma Holdings (XERS), Mineralys Therapeutics (MLYS), and iRadimed Corp (IRMD), show significant upside potential based on analyst target prices, with XERS at 38.16% higher, MLYS at 21.59%, and IRMD at 17.06%.

  • Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets relative to current prices could lead to potential downgrades if they are based on outdated information.

  • Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent developments in the companies and the healthcare industry.

[object Object]
Preview
4.0
10-31NASDAQ.COM
Oppenheimer Reaffirms Outperform Rating for Xeris Biopharma Holdings (XERS)

  • Analyst Coverage: Oppenheimer has maintained an "Outperform" rating for Xeris Biopharma Holdings (NasdaqGS:XERS) as of October 29, 2025, with an average one-year price target of $9.18/share, indicating a potential downside of 5.51% from its recent closing price.

  • Fund Sentiment: There has been an increase in institutional ownership of Xeris Biopharma, with 361 funds reporting positions, reflecting a 6.18% rise in the last quarter and a total of 104,118K shares owned by institutions.

  • Shareholder Activity: Notable shareholders like Vanguard and D. E. Shaw have adjusted their holdings, with Vanguard increasing its shares by 16.61% while D. E. Shaw raised its stake by 20.42%, despite both firms reducing their overall portfolio allocation in XERS.

  • Market Outlook: The put/call ratio for XERS stands at 0.12, suggesting a bullish sentiment among investors, while the projected annual revenue is expected to decrease slightly by 0.64%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Xeris Biopharma Holdings Inc (XERS) stock price today?

The current price of XERS is 6.72 USD — it has decreased -0.15 % in the last trading day.

arrow icon

What is Xeris Biopharma Holdings Inc (XERS)'s business?

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

arrow icon

What is the price predicton of XERS Stock?

Wall Street analysts forecast XERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XERS is 12.33 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Xeris Biopharma Holdings Inc (XERS)'s revenue for the last quarter?

Xeris Biopharma Holdings Inc revenue for the last quarter amounts to 74.38M USD, increased 37.06 % YoY.

arrow icon

What is Xeris Biopharma Holdings Inc (XERS)'s earnings per share (EPS) for the last quarter?

Xeris Biopharma Holdings Inc. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Xeris Biopharma Holdings Inc (XERS)'s fundamentals?

The market is revising Upward the revenue expectations for Xeris Biopharma Holdings, Inc. (XERS) for FY2025, with the revenue forecasts being adjusted by 0.33% over the past three months. During the same period, the stock price has changed by -14.39%.
arrow icon

How many employees does Xeris Biopharma Holdings Inc (XERS). have?

Xeris Biopharma Holdings Inc (XERS) has 394 emplpoyees as of December 05 2025.

arrow icon

What is Xeris Biopharma Holdings Inc (XERS) market cap?

Today XERS has the market capitalization of 1.12B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free